Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sabizabulin + sacituzumab govitecan-hziy
- Development stage
- Unknown
- Lead developer
- Veru
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
Sabizabulin + sacituzumab govitecan-hziy is a combination of two investigational anticancer agents. Sabizabulin is an oral small molecule that disrupts microtubule polymerization, leading to cell cycle arrest and apoptosis in cancer cells. Sacituzumab govitecan-hziy is an antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody targeting Trop-2, linked to SN-38, the active metabolite of irinotecan and a topoisomerase I inhibitor. Sacituzumab govitecan-hziy binds to Trop-2-expressing cancer cells, delivering SN-38 directly into the tumor cell where it induces DNA damage and cell death. This combination has been studied in clinical trials for advanced or metastatic cancers[3][4][5][6][8].
- Brand names
- Trodelvy
- Other names
- none
02
Targets
TUBB (Tubulin (alpha and beta subunits))TACSTD2 (Tumor-associated calcium signal transducer 2)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on sabizabulin + sacituzumab govitecan-hziy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sabizabulin + sacituzumab govitecan-hziy.